Merck's cancer candidates MK-4280 and MK-7684 show encouraging action in early-stage studies

|About: Merck & Co Inc. (MRK)|By:, SA News Editor

Preliminary data from Phase 1/2 dose-finding studies for Merck's (NYSE:MRK) anti-LAG-3 candidate MK-4280 and anti-TIGIT candidate MK-7684 showed acceptable safety profiles, no dose-limiting toxicities and early signs of anti-tumor activity as monotherapies and in combination with Keytruda (pembrolizumab). The results are being presented at SITC in Washington, DC.

LAG-3 and TIGIT are proteins that downregulate the immune response.

Subscribe for full text news in your inbox